<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20241031082010&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20241031082010&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 31 Oct 2024 12:20:11 +0000</lastbuilddate>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5;84(19):1850-1853. doi: 10.1016/j.jacc.2024.09.015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39477632</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.015>10.1016/j.jacc.2024.09.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477632</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Enrico Ammirati</dc:creator>
<dc:creator>Guglielmo Gallone</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?</dc:title>
<dc:identifier>pmid:39477632</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.015</dc:identifier>
</item>
<item>
<title>Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5;84(19):1839-1849. doi: 10.1016/j.jacc.2024.09.002.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target side effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We describe the impact of SoC therapy downtitration and withdrawal in patients already receiving aficamten in FOREST-HCM (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy; NCT04848506).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients receiving SoC therapy (beta-blocker, nondihydropyridine calcium-channel blocker, and/or disopyramide) were eligible for protocol-guided SoC downtitration and withdrawal at the discretion of the investigator and after achieving a stable dose of aficamten for ≥4 weeks. Successful SoC withdrawal was defined as at least a 50% dose-reduction in ≥1 medication. Adverse events (AEs) were prospectively evaluated 1 to 2 weeks after any SoC withdrawal.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 145 patients with oHCM who were followed for at least 24 weeks (mean age 60.5 ± 13.2 years; 44.8% female; 42% NYHA functional class III), 136 (93.8%) were receiving ≥1 SoC therapy; of those, 64 (47%) had an attempt at withdrawal, with 59 (92.2%) successful. Thirty-eight (64.4%) patients completely discontinued ≥1 medication, and 27 (45.8%) achieved aficamten monotherapy with 2 later restarting a SoC medication. There were no significant differences in baseline characteristics on day 1 in FOREST-HCM in those with a SoC-withdrawal vs no-withdrawal attempt. In patients who underwent successful SoC therapy withdrawal, NYHA functional class improved by ≥1 class in 79.2% from baseline, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score improved to 83.0 ± 15.8 points, and resting and Valsalva left ventricular outflow tract gradient improved to 14.3 ± 10.9 and 32.9 ± 21.4 mm Hg, respectively. N-terminal pro-B-type natriuretic peptide levels improved to a median of 220.0 pg/mL (Q1-Q3: 102.0-554.0.0 pg/mL) and high-sensitivity troponin I improved to a median of 6.0 ng/L (Q1-Q3:3.5-10.7 ng/L). Downtitration and withdrawal of SoC therapy did not impact these results (all P values for change were >;0.05), and these changes were similar in patients who did not undergo SoC therapy withdrawal. There were no serious AEs attributed to SoC withdrawal and treatment emergent AEs were similar between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39477631</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.002>10.1016/j.jacc.2024.09.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477631</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Lubna Choudhury</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Perry Elliott</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Michael E Nassif</dc:creator>
<dc:creator>Artur Oreziak</dc:creator>
<dc:creator>Anjali Tiku Owens</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Albree Tower-Rader</dc:creator>
<dc:creator>Florian Rader</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Sherif F Nagueh</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Stephen B Heitner</dc:creator>
<dc:creator>Daniel L Jacoby</dc:creator>
<dc:creator>Stuart Kupfer</dc:creator>
<dc:creator>Fady I Malik</dc:creator>
<dc:creator>Chiara Melloni</dc:creator>
<dc:creator>Lisa Meng</dc:creator>
<dc:creator>Jenny Wei</dc:creator>
<dc:creator>Mark V Sherrid</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>FOREST-HCM Investigators</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM</dc:title>
<dc:identifier>pmid:39477631</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.002</dc:identifier>
</item>
<item>
<title>TAVR in Patients with Moderate Aortic Stenosis and Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39477044/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10056-3. doi: 10.1016/j.jacc.2024.10.088. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39477044/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39477044</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.088>10.1016/j.jacc.2024.10.088</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39477044</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Philippe Généreux</dc:creator>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>TAVR in Patients with Moderate Aortic Stenosis and Heart Failure</dc:title>
<dc:identifier>pmid:39477044</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.088</dc:identifier>
</item>
<item>
<title>Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476841/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>Chronic itch is a debilitating symptom profoundly impacting the quality of life in patients with liver diseases like cholestasis. Activation of the human G-protein coupled receptor, MRGPRX4 (hX4), by bile acids (BAs) is implicated in promoting cholestasis itch. However, the detailed underlying mechanisms remain elusive. Here, we identified 3-sulfated BAs that are elevated in cholestatic patients with itch symptoms. We solved the cryo-EM structure of hX4-Gq in a complex with 3-phosphated...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 24:S0092-8674(24)01149-8. doi: 10.1016/j.cell.2024.10.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chronic itch is a debilitating symptom profoundly impacting the quality of life in patients with liver diseases like cholestasis. Activation of the human G-protein coupled receptor, MRGPRX4 (hX4), by bile acids (BAs) is implicated in promoting cholestasis itch. However, the detailed underlying mechanisms remain elusive. Here, we identified 3-sulfated BAs that are elevated in cholestatic patients with itch symptoms. We solved the cryo-EM structure of hX4-Gq in a complex with 3-phosphated deoxycholic acid (DCA-3P), a mimic of the endogenous 3-sulfated deoxycholic acid (DCA-3S). This structure revealed an unprecedented ligand-binding pocket in MRGPR family proteins, highlighting the crucial role of the 3-hydroxyl (3-OH) group on BAs in activating hX4. Guided by this structural information, we designed and developed compound 7 (C7), a BA derivative lacking the 3-OH. Notably, C7 effectively alleviates hepatic injury and fibrosis in liver disease models while significantly mitigating the itch side effects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476841/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39476841</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.001>10.1016/j.cell.2024.10.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476841</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jun Yang</dc:creator>
<dc:creator>Tianjun Zhao</dc:creator>
<dc:creator>Junping Fan</dc:creator>
<dc:creator>Huaibin Zou</dc:creator>
<dc:creator>Guangyi Lan</dc:creator>
<dc:creator>Fusheng Guo</dc:creator>
<dc:creator>Yaocheng Shi</dc:creator>
<dc:creator>Han Ke</dc:creator>
<dc:creator>Huasheng Yu</dc:creator>
<dc:creator>Zongwei Yue</dc:creator>
<dc:creator>Xin Wang</dc:creator>
<dc:creator>Yingjie Bai</dc:creator>
<dc:creator>Shuai Li</dc:creator>
<dc:creator>Yingjun Liu</dc:creator>
<dc:creator>Xiaoming Wang</dc:creator>
<dc:creator>Yu Chen</dc:creator>
<dc:creator>Yulong Li</dc:creator>
<dc:creator>Xiaoguang Lei</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch</dc:title>
<dc:identifier>pmid:39476841</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.001</dc:identifier>
</item>
<item>
<title>An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of Oceania</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>Genetic variation in host immunity impacts the disproportionate burden of infectious diseases that can be experienced by First Nations peoples. Polymorphic human leukocyte antigen (HLA) class I and killer cell immunoglobulin-like receptors (KIRs) are key regulators of natural killer (NK) cells, which mediate early infection control. How this variation impacts their responses across populations is unclear. We show that HLA-A^(∗)24:02 became the dominant ligand for inhibitory KIR3DL1 in First...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 25:S0092-8674(24)01153-X. doi: 10.1016/j.cell.2024.10.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Genetic variation in host immunity impacts the disproportionate burden of infectious diseases that can be experienced by First Nations peoples. Polymorphic human leukocyte antigen (HLA) class I and killer cell immunoglobulin-like receptors (KIRs) are key regulators of natural killer (NK) cells, which mediate early infection control. How this variation impacts their responses across populations is unclear. We show that HLA-A<sup>∗</sup>24:02 became the dominant ligand for inhibitory KIR3DL1 in First Nations peoples across Oceania, through positive natural selection. We identify KIR3DL1<sup>∗</sup>114, widespread across and unique to Oceania, as an allele lineage derived from archaic humans. KIR3DL1<sup>∗</sup>114<sup>+</sup>NK cells from First Nations Australian donors are inhibited through binding HLA-A<sup>∗</sup>24:02. The KIR3DL1<sup>∗</sup>114 lineage is defined by phenylalanine at residue 166. Structural and binding studies show phenylalanine 166 forms multiple unique contacts with HLA-peptide complexes, increasing both affinity and specificity. Accordingly, assessing immunogenetic variation and the functional implications for immunity are fundamental toward understanding population-based disease associations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39476840</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.005>10.1016/j.cell.2024.10.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476840</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Liyen Loh</dc:creator>
<dc:creator>Philippa M Saunders</dc:creator>
<dc:creator>Camilla Faoro</dc:creator>
<dc:creator>Neus Font-Porterias</dc:creator>
<dc:creator>Neda Nemat-Gorgani</dc:creator>
<dc:creator>Genelle F Harrison</dc:creator>
<dc:creator>Suraju Sadeeq</dc:creator>
<dc:creator>Luca Hensen</dc:creator>
<dc:creator>Shu Cheng Wong</dc:creator>
<dc:creator>Jacqueline Widjaja</dc:creator>
<dc:creator>E Bridie Clemens</dc:creator>
<dc:creator>Shiying Zhu</dc:creator>
<dc:creator>Katherine M Kichula</dc:creator>
<dc:creator>Sudan Tao</dc:creator>
<dc:creator>Faming Zhu</dc:creator>
<dc:creator>Gonzalo Montero-Martin</dc:creator>
<dc:creator>Marcelo Fernandez-Vina</dc:creator>
<dc:creator>Lisbeth A Guethlein</dc:creator>
<dc:creator>Julian P Vivian</dc:creator>
<dc:creator>Jane Davies</dc:creator>
<dc:creator>Alexander J Mentzer</dc:creator>
<dc:creator>Stephen J Oppenheimer</dc:creator>
<dc:creator>William Pomat</dc:creator>
<dc:creator>Alexander G Ioannidis</dc:creator>
<dc:creator>Carmina Barberena-Jonas</dc:creator>
<dc:creator>Oceanian Genome Variation Project Consortium</dc:creator>
<dc:creator>Andrés Moreno-Estrada</dc:creator>
<dc:creator>Adrian Miller</dc:creator>
<dc:creator>Peter Parham</dc:creator>
<dc:creator>Jamie Rossjohn</dc:creator>
<dc:creator>Steven Y C Tong</dc:creator>
<dc:creator>Katherine Kedzierska</dc:creator>
<dc:creator>Andrew G Brooks</dc:creator>
<dc:creator>Paul J Norman</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of Oceania</dc:title>
<dc:identifier>pmid:39476840</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.005</dc:identifier>
</item>
<item>
<title>Stem cell activity-coupled suppression of endogenous retrovirus governs adult tissue regeneration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>Mammalian retrotransposons constitute 40% of the genome. During tissue regeneration, adult stem cells coordinately repress retrotransposons and activate lineage genes, but how this coordination is controlled is poorly understood. Here, we observed that dynamic expression of histone methyltransferase SETDB1 (a retrotransposon repressor) closely mirrors stem cell activities in murine skin. SETDB1 ablation leads to the reactivation of endogenous retroviruses (ERVs, a type of retrotransposon) and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 23:S0092-8674(24)01155-3. doi: 10.1016/j.cell.2024.10.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mammalian retrotransposons constitute 40% of the genome. During tissue regeneration, adult stem cells coordinately repress retrotransposons and activate lineage genes, but how this coordination is controlled is poorly understood. Here, we observed that dynamic expression of histone methyltransferase SETDB1 (a retrotransposon repressor) closely mirrors stem cell activities in murine skin. SETDB1 ablation leads to the reactivation of endogenous retroviruses (ERVs, a type of retrotransposon) and the assembly of viral-like particles, resulting in hair loss and stem cell exhaustion that is reversible by antiviral drugs. Mechanistically, at least two molecularly and spatially distinct pathways are responsible: antiviral defense mediated by hair follicle stem cells and progenitors and antiviral-independent response due to replication stress in transient amplifying cells. ERV reactivation is promoted by DNA demethylase ten-eleven translocation (TET)-mediated hydroxymethylation and recapitulated by ablating cell fate transcription factors. Together, we demonstrated ERV silencing is coupled with stem cell activity and essential for adult hair regeneration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39476839</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.007>10.1016/j.cell.2024.10.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476839</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ying Lyu</dc:creator>
<dc:creator>Soo Jin Kim</dc:creator>
<dc:creator>Ericka S Humphrey</dc:creator>
<dc:creator>Richa Nayak</dc:creator>
<dc:creator>Yinglu Guan</dc:creator>
<dc:creator>Qingnan Liang</dc:creator>
<dc:creator>Kun Hee Kim</dc:creator>
<dc:creator>Yukun Tan</dc:creator>
<dc:creator>Jinzhuang Dou</dc:creator>
<dc:creator>Huandong Sun</dc:creator>
<dc:creator>Xingzhi Song</dc:creator>
<dc:creator>Priyadharsini Nagarajan</dc:creator>
<dc:creator>Kamryn N Gerner-Mauro</dc:creator>
<dc:creator>Kevin Jin</dc:creator>
<dc:creator>Virginia Liu</dc:creator>
<dc:creator>Rehman H Hassan</dc:creator>
<dc:creator>Miranda L Johnson</dc:creator>
<dc:creator>Lisa P Deliu</dc:creator>
<dc:creator>Yun You</dc:creator>
<dc:creator>Anurag Sharma</dc:creator>
<dc:creator>H Amalia Pasolli</dc:creator>
<dc:creator>Yue Lu</dc:creator>
<dc:creator>Jianhua Zhang</dc:creator>
<dc:creator>Vakul Mohanty</dc:creator>
<dc:creator>Ken Chen</dc:creator>
<dc:creator>Youn Joo Yang</dc:creator>
<dc:creator>Taiping Chen</dc:creator>
<dc:creator>Yejing Ge</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Stem cell activity-coupled suppression of endogenous retrovirus governs adult tissue regeneration</dc:title>
<dc:identifier>pmid:39476839</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.007</dc:identifier>
</item>
<item>
<title>Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study, the KCCQ had strong psychometric properties in patients with severe TR, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe TR as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as TTVI, in rigorously controlled trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4266. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Improving patients' health status is a key goal of treating tricuspid regurgitation (TR). The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a heart failure disease-specific health status measure used to capture the health status impact of TR and the benefit of transcatheter tricuspid valve intervention (TTVI), but its validity in this clinical setting is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the psychometric properties of the KCCQ in patients with TR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from patients with severe TR enrolled in 11 manufacturer-sponsored trials of TTVI. The data were transferred to the US Food and Drug Administration to harmonize and anonymize prior to analysis by an independent center. Data were collected from December 2015 to April 2023, and data analysis was performed from July to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Prespecified analyses included evaluation of internal consistency, reproducibility, responsiveness, construct validity, and predictive validity. Outcomes were determined using Cronbach α, score comparisons, intraclass correlation, Cohen d, Spearman correlations with best available reference measures, and association of scores and changes in scores with risk of subsequent clinical events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study cohort was composed of 2693 patients enrolled in either single-arm (n = 1517) or randomized (n = 1176) investigations of TTVI. Mean (SD) patient age was 78.6 (8.0) years, 1658 of 2693 patients (61.6%) were female, and the mean (SD) baseline KCCQ Overall Summary (KCCQ-OS) score was 50 (23). There was strong internal consistency within individual domains (Cronbach α, .77-.83). Among clinically stable patients between 1 and 6 months, there were small mean changes in KCCQ domain and summary scores (differences of -0.1 to 1.9 points), demonstrating reproducibility. In contrast, domain and summary scores of patients who underwent TTVI showed large improvements at 1 month after treatment (mean changes, 12.1-21.4 points), indicating excellent perceived responsiveness. Construct validity was moderately strong when domains were compared with best available reference measures (Spearman correlations, 0.47-0.69). In both cross-sectional and longitudinal analyses, the KCCQ-OS was associated with clinical events, with lower scores associated with an increased risk of mortality (hazard ratio, 1.34 per 10-point decrement; 95% CI, 1.22-1.47) and heart failure hospitalization (hazard ratio, 1.24 per 10-point decrement; 95% CI, 1.17-1.31).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study, the KCCQ had strong psychometric properties in patients with severe TR, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe TR as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as TTVI, in rigorously controlled trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39476153</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4266>10.1001/jamacardio.2024.4266</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476153</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Kensey Gosch</dc:creator>
<dc:creator>Shannon M Dunlay</dc:creator>
<dc:creator>Danielle M Olds</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>Fraser D Bocell</dc:creator>
<dc:creator>Changfu Wu</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation</dc:title>
<dc:identifier>pmid:39476153</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4266</dc:identifier>
</item>
<item>
<title>Measuring Health Status in Patients With Tricuspid Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39476024/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4287. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39476024/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39476024</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4287>10.1001/jamacardio.2024.4287</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39476024</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Measuring Health Status in Patients With Tricuspid Regurgitation</dc:title>
<dc:identifier>pmid:39476024</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4287</dc:identifier>
</item>
<item>
<title>Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation - a Post-hoc Analysis of the MATTERHORN Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 30. doi: 10.1161/CIRCULATIONAHA.124.072648. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39475706</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072648>10.1161/CIRCULATIONAHA.124.072648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475706</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Felix Rudolph</dc:creator>
<dc:creator>Martin Geyer</dc:creator>
<dc:creator>Stephan Baldus</dc:creator>
<dc:creator>Valeria Maria De Luca</dc:creator>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Roman Pfister</dc:creator>
<dc:creator>Jan Gummert</dc:creator>
<dc:creator>Mirjam Kessler</dc:creator>
<dc:creator>Peter Boekstegers</dc:creator>
<dc:creator>Edith Lubos</dc:creator>
<dc:creator>Jörg Schröder</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Thomas Walther</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Ingo Eitel</dc:creator>
<dc:creator>Ulrich Fischer-Rasokat</dc:creator>
<dc:creator>Alexander Bufe</dc:creator>
<dc:creator>Alexander Schmeisser</dc:creator>
<dc:creator>Hüseyin Ince</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Christian Hagl</dc:creator>
<dc:creator>Thilo Noack</dc:creator>
<dc:creator>Sebastian Reith</dc:creator>
<dc:creator>Harald Beucher</dc:creator>
<dc:creator>Hermann Reichenspurner</dc:creator>
<dc:creator>Wolfgang Rottbauer</dc:creator>
<dc:creator>Paul Christian Schulze</dc:creator>
<dc:creator>Wiebke Müller</dc:creator>
<dc:creator>Julia Frank</dc:creator>
<dc:creator>Claudia Michalik</dc:creator>
<dc:creator>Martin Hellmich</dc:creator>
<dc:creator>Thorsten Wahlers</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>Christos Iliadis</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation - a Post-hoc Analysis of the MATTERHORN Trial</dc:title>
<dc:identifier>pmid:39475706</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072648</dc:identifier>
</item>
<item>
<title>TAVR in Young Patients With Aortic Stenosis: Appropriate Use or Indication Creep?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475343/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4300. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475343/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39475343</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4300>10.1001/jamacardio.2024.4300</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475343</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert O Bonow</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>TAVR in Young Patients With Aortic Stenosis: Appropriate Use or Indication Creep?</dc:title>
<dc:identifier>pmid:39475343</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4300</dc:identifier>
</item>
<item>
<title>Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39475333/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among US patients receiving BEV TAVR for severe aortic stenosis in the low-surgical risk era, those younger than 65 years represent a small subset. Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts. These observations suggest that heart team decision-making regarding TAVR for most patients in this age group is clinically valid.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 30. doi: 10.1001/jamacardio.2024.4237. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Guidelines advise heart team assessment for all patients with aortic stenosis, with surgical aortic valve replacement recommended for patients younger than 65 years or with a life expectancy greater than 20 years. If bioprosthetic valves are selected, repeat procedures may be needed given limited durability of tissue valves; however, younger patients with aortic stenosis may have major comorbidities that can limit life expectancy, impacting decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To characterize patients younger than 65 years who received transcatheter aortic valve replacement (TAVR) and compare their outcomes with patients aged 65 to 80 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This retrospective registry-based analysis used data on 139 695 patients from the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry, inclusive of patients 80 years and younger undergoing TAVR from August 2019 to September 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Balloon-expandable valve (BEV) TAVR with the SAPIEN family of devices.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Comorbidities (heart failure, coronary artery disease, dialysis, and others) and outcomes (death, stroke, and hospital readmission) of patients younger than 65 years compared to patients aged 65 to 80 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the years surveyed, 13 849 registry patients (5.7%) were younger than 65 years, 125 846 (52.1%) were aged 65 to 80 years, and 101 725 (42.1%) were 80 years and older. Among those younger than 65, the mean (SD) age was 59.7 (4.8) years, and 9068 of 13 849 patients (65.5%) were male. Among those aged 65 to 80 years, the mean (SD) age was 74.1 (4.2) years, and 77 817 of 125 843 patients (61.8%) were male. Those younger than 65 years were more likely to have a bicuspid aortic valve than those aged 65 to 80 years (3472/13 755 [25.2%] vs 9552/125 001 [7.6%], respectively; P &lt; .001). They were more likely to have congestive heart failure, chronic lung disease, diabetes, immunocompromise, and end stage kidney disease receiving dialysis. Patients younger than 65 years had worse baseline quality of life (mean [SD] Kansas City Cardiomyopathy Questionnaire score, 47.7 [26.3] vs 52.9 [25.8], respectively; P &lt; .001) and mean (SD) gait speed (5-meter walk test, 6.6 [5.8] seconds vs 7.0 [4.9] seconds, respectively; P &lt; .001) than those aged 65 to 80 years. At 1 year, patients younger than 65 years had significantly higher readmission rates (2740 [28.2%] vs 23 178 [26.1%]; P &lt; .001) and all-cause mortality (908 [9.9%] vs 6877 [8.2%]; P &lt; .001) than older patients. When propensity matched, younger patients still had higher 1-year readmission rates (2732 [28.2%] vs 2589 [26.8%]; P &lt; .03) with similar mortality to their older counterparts (905 [9.9%] vs 827 [10.1%]; P = .55).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among US patients receiving BEV TAVR for severe aortic stenosis in the low-surgical risk era, those younger than 65 years represent a small subset. Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts. These observations suggest that heart team decision-making regarding TAVR for most patients in this age group is clinically valid.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39475333/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39475333</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4237>10.1001/jamacardio.2024.4237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39475333</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan Coylewright</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Abhijeet Dhoble</dc:creator>
<dc:creator>Aaron Horne</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Vinod Thourani</dc:creator>
<dc:creator>Tamim M Nazif</dc:creator>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era</dc:title>
<dc:identifier>pmid:39475333</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4237</dc:identifier>
</item>
<item>
<title>Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation: the ACCESS-TAVI randomized trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39474906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: With regard to the composite of major or minor access-related vascular complications, a combined suture-/plug-based VCD strategy was superior to a suturebased VCD strategy for vascular access closure in patients undergoing TF-TAVI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae784. doi: 10.1093/eurheartj/ehae784. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Data from randomized trials investigating different access closure strategies after transfemoral transcatheter aortic valve implantation (TF-TAVI) remain scarce. In this study, two vascular closure device (VCD) strategies to achieve hemostasis after TF-TAVI were compared.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The ACCESS-TAVI (Comparison of Strategies for Vascular ACCESS Closure after Transcatheter Aortic Valve Implantation) is a prospective, multicenter trial in which patients undergoing TF-TAVI were randomly assigned to a strategy with a combined suture-/plug-based VCD strategy (suture/plug group) using one ProGlideTM/ProStyleTM (Abbott Vascular) and one Angio-Seal® (Terumo) versus a suture-based VCD strategy (suture-only group) using two ProGlidesTM/ProStylesTM. The primary endpoint was a composite of major or minor access site-related vascular complications during index hospitalization according to Valve Academic Research Consortium (VARC)-3 criteria. Key secondary endpoints included time to hemostasis, VARC-3 bleeding type ≥2 and all-cause mortality over 30 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between September 2022 and April 2024, 454 patients were randomized. The primary endpoint occurred in 27% (62/230) in the suture/plug group and 54% (121/224) in the suture-only group (relative risk [RR] 0.55 [95% confidence interval: 0.44;0.68]; p&lt;0.001). Time to hemostasis was significantly shorter in the suture/plug group compared to the suture-only group (108±208 s vs. 206±171 s; p &lt;0.001). At 30 days, bleeding type ≥2 occurred less often in the suture/plug group compared to the sutureonly group (6.2% vs. 12.1%, RR 0.66 [0.43;1.02]; p=0.032), with no significant difference in mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: With regard to the composite of major or minor access-related vascular complications, a combined suture-/plug-based VCD strategy was superior to a suturebased VCD strategy for vascular access closure in patients undergoing TF-TAVI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39474906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39474906</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae784>10.1093/eurheartj/ehae784</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39474906</guid>
<pubDate>Wed, 30 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Tobias Rheude</dc:creator>
<dc:creator>Hendrik Ruge</dc:creator>
<dc:creator>Niklas Altaner</dc:creator>
<dc:creator>Costanza Pellegrini</dc:creator>
<dc:creator>Hector Alvarez Covarrubias</dc:creator>
<dc:creator>N Patrick Mayr</dc:creator>
<dc:creator>Salvatore Cassese</dc:creator>
<dc:creator>Sebastian Kufner</dc:creator>
<dc:creator>Yousuke Taniguchi</dc:creator>
<dc:creator>Christian Thilo</dc:creator>
<dc:creator>Markus Klos</dc:creator>
<dc:creator>Magdalena Erlebach</dc:creator>
<dc:creator>Simon Schneider</dc:creator>
<dc:creator>Martin Jurisic</dc:creator>
<dc:creator>Karl-Ludwig Laugwitz</dc:creator>
<dc:creator>Rüdiger Lange</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Adnan Kastrati</dc:creator>
<dc:creator>Markus Krane</dc:creator>
<dc:creator>Erion Xhepa</dc:creator>
<dc:creator>Michael Joner</dc:creator>
<dc:date>2024-10-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation: the ACCESS-TAVI randomized trial</dc:title>
<dc:identifier>pmid:39474906</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae784</dc:identifier>
</item>
<item>
<title>Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471883/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TriClip was safe and effective in the full randomized cohort of TRILUMINATE Pivotal with significant TR reduction and improvements in six-minute walk distance and health status. Rates of all-cause mortality or TV surgery and HFH through 1 year were not reduced by T-TEER.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 23:S0735-1097(24)10054-X. doi: 10.1016/j.jacc.2024.10.086. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Tricuspid regurgitation (TR) is a right-sided valvular disease independently associated with morbidity and mortality. The TRILUMINATE Pivotal trial is the first randomized, controlled trial assessing the impact of TR reduction with tricuspid transcatheter edge-to-edge repair (T-TEER).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: Outcomes from the full randomized cohort of the TRILUMINATE Pivotal trial have not been previously reported, and the additional enrollment may further support the safety and effectiveness of T-TEER through 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The TRILUMINATE Pivotal trial is an international RCT of T-TEER with the TriClip device in patients with symptomatic, severe TR. Adaptive trial design allowed enrollment past the primary analysis population. The primary outcome was a hierarchical composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations (HFH), and quality-of-life improvement measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) at 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between August 21, 2019 and June 29, 2022, 572 subjects were randomized, including the primary cohort (n=350) and subsequent enrollment (n=222). Subjects were elderly (78.1±7.8 years) and predominantly female (58.9%), with atrial fibrillation (87.8%) and prior HFH (23.8%). The primary endpoint was met for the full cohort (win ratio=1.84, p&lt;0.0001). Freedom from all-cause mortality and tricuspid valve surgery through 12 months was 90.6% and 89.9% for the device and control groups, respectively (p=0.82). Annualized HFH rate was comparable between device and control subjects (0.17 vs 0.20 events/patient-year, p=0.40). A significant treatment effect was observed for change in quality of life with 49.5% of device subjects achieving a ≥15-point KCCQ score improvement (compared to 25.6% of control subjects, p&lt;0.0001). All secondary endpoints favored T-TEER: moderate or less TR at 30 days (88.9% vs 5.3%, p&lt;0.0001), KCCQ change at 1 year (13.0±1.4 vs -0.5±1.4 points, p&lt;0.0001), and six-minute walk distance change at 1 year (1.7±7.5 vs -27.4±7.4 meters, p&lt;0.0001). Freedom from major adverse events was 98.9% for T-TEER (vs. performance goal: 90%, p&lt;0.0001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TriClip was safe and effective in the full randomized cohort of TRILUMINATE Pivotal with significant TR reduction and improvements in six-minute walk distance and health status. Rates of all-cause mortality or TV surgery and HFH through 1 year were not reduced by T-TEER.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471883/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471883</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.086>10.1016/j.jacc.2024.10.086</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471883</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Brian K Whisenant</dc:creator>
<dc:creator>Nadira Hamid</dc:creator>
<dc:creator>Hursh Naik</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:creator>Peter Tadros</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Gagan D Singh</dc:creator>
<dc:creator>Neil P Fam</dc:creator>
<dc:creator>Saibal Kar</dc:creator>
<dc:creator>Shamir R Mehta</dc:creator>
<dc:creator>Richard Bae</dc:creator>
<dc:creator>Nishant K Sekaran</dc:creator>
<dc:creator>Travis Warner</dc:creator>
<dc:creator>Moody Makar</dc:creator>
<dc:creator>George Zorn</dc:creator>
<dc:creator>Raymond Benza</dc:creator>
<dc:creator>Ulrich P Jorde</dc:creator>
<dc:creator>Patrick M McCarthy</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Qian Ren</dc:creator>
<dc:creator>Phillip M Trusty</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>David H Adams</dc:creator>
<dc:creator>TRILUMINATE Pivotal Investigators</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort</dc:title>
<dc:identifier>pmid:39471883</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.086</dc:identifier>
</item>
<item>
<title>Solidifying our Understanding of T-TEER Outcomes: Insights from the PASTE Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 24:S0735-1097(24)10299-9. doi: 10.1016/j.jacc.2024.10.098. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471882</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.098>10.1016/j.jacc.2024.10.098</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471882</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Solidifying our Understanding of T-TEER Outcomes: Insights from the PASTE Registry</dc:title>
<dc:identifier>pmid:39471882</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.098</dc:identifier>
</item>
<item>
<title>Decreasing Unnecessary Invasive Coronary Angiograms with Photon-Counting Detector Coronary Computed Tomography Angiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471881/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 18:S0735-1097(24)10052-6. doi: 10.1016/j.jacc.2024.10.084. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471881/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471881</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.084>10.1016/j.jacc.2024.10.084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471881</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrew J Einstein</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Decreasing Unnecessary Invasive Coronary Angiograms with Photon-Counting Detector Coronary Computed Tomography Angiography</dc:title>
<dc:identifier>pmid:39471881</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.084</dc:identifier>
</item>
<item>
<title>Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471811/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection by simian-human immunodeficiency virus (SHIV). In four macaques with vaccine-induced neutralizing responses, SHIV infection boosted plasma neutralization to 45%-77% breadth (geometric mean 50% inhibitory dilution [ID(50)] ∼100) on a 208-strain panel....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 23:S0092-8674(24)01151-6. doi: 10.1016/j.cell.2024.10.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection by simian-human immunodeficiency virus (SHIV). In four macaques with vaccine-induced neutralizing responses, SHIV infection boosted plasma neutralization to 45%-77% breadth (geometric mean 50% inhibitory dilution [ID<sub>50</sub>] ∼100) on a 208-strain panel. Molecular dissection of these responses by antibody isolation and cryo-electron microscopy (cryo-EM) structure determination revealed 15 of 16 antibody lineages with cross-clade neutralization to be directed toward the fusion-peptide site of vulnerability. In each macaque, isolated antibodies from memory B cells recapitulated the plasma-neutralizing response, with fusion-peptide-binding antibodies reaching breadths of 40%-60% (50% inhibitory concentration [IC<sub>50</sub>] &lt; 50 μg/mL) and total lineage-concentrations estimates of 50-200 μg/mL. Longitudinal mapping indicated that these responses arose prior to SHIV infection. Collectively, these results provide in vivo molecular examples for one to a few B cell lineages affording potent, broadly neutralizing plasma responses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471811/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471811</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.003>10.1016/j.cell.2024.10.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471811</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Hua Wang</dc:creator>
<dc:creator>Cheng Cheng</dc:creator>
<dc:creator>James L Dal Santo</dc:creator>
<dc:creator>Chen-Hsiang Shen</dc:creator>
<dc:creator>Tatsiana Bylund</dc:creator>
<dc:creator>Amy R Henry</dc:creator>
<dc:creator>Colin A Howe</dc:creator>
<dc:creator>Juyun Hwang</dc:creator>
<dc:creator>Nicholas C Morano</dc:creator>
<dc:creator>Daniel J Morris</dc:creator>
<dc:creator>Sergei Pletnev</dc:creator>
<dc:creator>Ryan S Roark</dc:creator>
<dc:creator>Tongqing Zhou</dc:creator>
<dc:creator>Bryan T Hansen</dc:creator>
<dc:creator>Forrest H Hoyt</dc:creator>
<dc:creator>Timothy S Johnston</dc:creator>
<dc:creator>Shuyi Wang</dc:creator>
<dc:creator>Baoshan Zhang</dc:creator>
<dc:creator>David R Ambrozak</dc:creator>
<dc:creator>Jordan E Becker</dc:creator>
<dc:creator>Michael F Bender</dc:creator>
<dc:creator>Anita Changela</dc:creator>
<dc:creator>Ridhi Chaudhary</dc:creator>
<dc:creator>Martin Corcoran</dc:creator>
<dc:creator>Angela R Corrigan</dc:creator>
<dc:creator>Kathryn E Foulds</dc:creator>
<dc:creator>Yicheng Guo</dc:creator>
<dc:creator>Myungjin Lee</dc:creator>
<dc:creator>Yingying Li</dc:creator>
<dc:creator>Bob C Lin</dc:creator>
<dc:creator>Tracy Liu</dc:creator>
<dc:creator>Mark K Louder</dc:creator>
<dc:creator>Marco Mandolesi</dc:creator>
<dc:creator>Rosemarie D Mason</dc:creator>
<dc:creator>Krisha McKee</dc:creator>
<dc:creator>Vinod Nair</dc:creator>
<dc:creator>Sijy O'Dell</dc:creator>
<dc:creator>Adam S Olia</dc:creator>
<dc:creator>Li Ou</dc:creator>
<dc:creator>Amarendra Pegu</dc:creator>
<dc:creator>Nagarajan Raju</dc:creator>
<dc:creator>Reda Rawi</dc:creator>
<dc:creator>Jesmine Roberts-Torres</dc:creator>
<dc:creator>Edward K Sarfo</dc:creator>
<dc:creator>Mallika Sastry</dc:creator>
<dc:creator>Andrew J Schaub</dc:creator>
<dc:creator>Stephen D Schmidt</dc:creator>
<dc:creator>Chaim A Schramm</dc:creator>
<dc:creator>Cindi L Schwartz</dc:creator>
<dc:creator>Sarah C Smith</dc:creator>
<dc:creator>Tyler Stephens</dc:creator>
<dc:creator>Jonathan Stuckey</dc:creator>
<dc:creator>I-Ting Teng</dc:creator>
<dc:creator>John-Paul Todd</dc:creator>
<dc:creator>Yaroslav Tsybovsky</dc:creator>
<dc:creator>David J Van Wazer</dc:creator>
<dc:creator>Shuishu Wang</dc:creator>
<dc:creator>Nicole A Doria-Rose</dc:creator>
<dc:creator>Elizabeth R Fischer</dc:creator>
<dc:creator>Ivelin S Georgiev</dc:creator>
<dc:creator>Gunilla B Karlsson Hedestam</dc:creator>
<dc:creator>Zizhang Sheng</dc:creator>
<dc:creator>Ruth A Woodward</dc:creator>
<dc:creator>Daniel C Douek</dc:creator>
<dc:creator>Richard A Koup</dc:creator>
<dc:creator>Theodore C Pierson</dc:creator>
<dc:creator>Lawrence Shapiro</dc:creator>
<dc:creator>George M Shaw</dc:creator>
<dc:creator>John R Mascola</dc:creator>
<dc:creator>Peter D Kwong</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques</dc:title>
<dc:identifier>pmid:39471811</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.003</dc:identifier>
</item>
<item>
<title>The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471810/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>Type III CRISPR systems provide immunity against genetic invaders through the production of cyclic oligo-adenylate (cA(n)) molecules that activate effector proteins that contain CRISPR-associated Rossman fold (CARF) domains. Here, we characterized the function and structure of an effector in which the CARF domain is fused to an adenosine deaminase domain, CRISPR-associated adenosine deaminase 1 (Cad1). We show that upon binding of cA(4) or cA(6) to its CARF domain, Cad1 converts ATP to ITP, both...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 24:S0092-8674(24)01150-4. doi: 10.1016/j.cell.2024.10.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Type III CRISPR systems provide immunity against genetic invaders through the production of cyclic oligo-adenylate (cA<sub>n</sub>) molecules that activate effector proteins that contain CRISPR-associated Rossman fold (CARF) domains. Here, we characterized the function and structure of an effector in which the CARF domain is fused to an adenosine deaminase domain, CRISPR-associated adenosine deaminase 1 (Cad1). We show that upon binding of cA<sub>4</sub> or cA<sub>6</sub> to its CARF domain, Cad1 converts ATP to ITP, both in vivo and in vitro. Cryoelectron microscopy (cryo-EM) structural studies on full-length Cad1 reveal an hexameric assembly composed of a trimer of dimers, with bound ATP at inter-domain sites required for activity and ATP/ITP within deaminase active sites. Upon synthesis of cA<sub>n</sub> during phage infection, Cad1 activation leads to a growth arrest of the host that prevents viral propagation. Our findings reveal that CRISPR-Cas systems employ a wide range of molecular mechanisms beyond nucleic acid degradation to provide adaptive immunity in prokaryotes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471810/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471810</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.002>10.1016/j.cell.2024.10.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471810</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Christian F Baca</dc:creator>
<dc:creator>Puja Majumder</dc:creator>
<dc:creator>James H Hickling</dc:creator>
<dc:creator>Linzhi Ye</dc:creator>
<dc:creator>Marianna Teplova</dc:creator>
<dc:creator>Sean F Brady</dc:creator>
<dc:creator>Dinshaw J Patel</dc:creator>
<dc:creator>Luciano A Marraffini</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity</dc:title>
<dc:identifier>pmid:39471810</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.002</dc:identifier>
</item>
<item>
<title>Multiparameter imaging reveals clinically relevant cancer cell-stroma interaction dynamics in head and neck cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471809/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>Epithelial tumors are characterized by abundant inter- and intra-tumor heterogeneity, which complicates diagnostics and treatment. The contribution of cancer-stroma interactions to this heterogeneity is poorly understood. Here, we report a paradigm to quantify phenotypic diversity in head and neck squamous cell carcinoma (HNSCC) with single-cell resolution. By combining cell-state markers with morphological features, we identify phenotypic signatures that correlate with clinical features,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 22:S0092-8674(24)01146-2. doi: 10.1016/j.cell.2024.09.046. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Epithelial tumors are characterized by abundant inter- and intra-tumor heterogeneity, which complicates diagnostics and treatment. The contribution of cancer-stroma interactions to this heterogeneity is poorly understood. Here, we report a paradigm to quantify phenotypic diversity in head and neck squamous cell carcinoma (HNSCC) with single-cell resolution. By combining cell-state markers with morphological features, we identify phenotypic signatures that correlate with clinical features, including metastasis and recurrence. Integration of tumor and stromal signatures reveals that partial epithelial-mesenchymal transition (pEMT) renders disease outcome highly sensitive to stromal composition, generating a strong prognostic and predictive signature. Spatial transcriptomics and subsequent analyses of cancer spheroid dynamics identify the cancer-associated fibroblast-pEMT axis as a nexus for intercompartmental signaling that reprograms pEMT cells into an invasive phenotype. Taken together, we establish a paradigm to identify clinically relevant tumor phenotypes and discover a cell-state-dependent interplay between stromal and epithelial compartments that drives cancer aggression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471809/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471809</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.046>10.1016/j.cell.2024.09.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471809</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Karolina Punovuori</dc:creator>
<dc:creator>Fabien Bertillot</dc:creator>
<dc:creator>Yekaterina A Miroshnikova</dc:creator>
<dc:creator>Mirjam I Binner</dc:creator>
<dc:creator>Satu-Marja Myllymäki</dc:creator>
<dc:creator>Gautier Follain</dc:creator>
<dc:creator>Kai Kruse</dc:creator>
<dc:creator>Johannes Routila</dc:creator>
<dc:creator>Teemu Huusko</dc:creator>
<dc:creator>Teijo Pellinen</dc:creator>
<dc:creator>Jaana Hagström</dc:creator>
<dc:creator>Noemi Kedei</dc:creator>
<dc:creator>Sami Ventelä</dc:creator>
<dc:creator>Antti Mäkitie</dc:creator>
<dc:creator>Johanna Ivaska</dc:creator>
<dc:creator>Sara A Wickström</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiparameter imaging reveals clinically relevant cancer cell-stroma interaction dynamics in head and neck cancer</dc:title>
<dc:identifier>pmid:39471809</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.046</dc:identifier>
</item>
<item>
<title>The inflammatory and oxidative phenotype of gestational diabetes is epigenetically transmitted to the offspring: role of methyltransferase MLL1-induced H3K4me3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471481/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Such proof-of-concept study shows persistence of MLL1-dependent H3K4me3 in offspring born to GD women, suggesting an epigenetic-driven transmission of maternal phenotype. These findings may pave the way for pharmacological reprogramming of adverse histone modifications to mitigate abnormal phenotypes underlying early ASCVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae688. doi: 10.1093/eurheartj/ehae688. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Hyperglycaemia during gestational diabetes (GD) predisposes women and their offspring to later cardiometabolic disease. The hyperglycaemia-mediated epigenetic changes remain to be elucidated. Methyltransferase MLL1-induced trimethylation of histone 3 at lysine 4 (H3K4me3) activates inflammatory and oxidative phenotype. This epigenetic mark in GD women and its transmission to the offspring were investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Peripheral blood mononuclear cells (PBMC) were collected from GD and control (C) women and also from adolescents born to women of both groups. Endothelial human umbilical vein endothelial cells (HUVEC) and cord blood mononuclear cells (CBMC) were from umbilical cords. The NF-κBp65 and NOX4 expressions were investigated by reverse transcription quantitative polymerase chain reaction and immunofluorescence (IF). MLL1 and H3K4me3 were investigated by immunoblotting and IF. H3K4me3 on NF-κBp65 and NOX4 promoters was studied by chromatin immunoprecipitation. Superoxide anion generation was measured by electron spin resonance spectroscopy. Plasma cytokines were measured by enzyme-linked immunosorbent assay. To investigate the role of MLL1, HUVEC were exposed to inhibitor MM102 or siRNA transfection.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: PBMC, CBMC, and HUVEC showed an increase of NF-κBp65, IL-6, ICAM-1, MCP-1, and VCAM-1 mRNAs. These findings were associated with H3K4me3 enrichment in the promoter of NF-κBp65. Elevated H3K4me3 and cytokine levels were observed in GD adolescents. MLL1 drives H3K4me3 not only on NF-kB p65, but also on NOX4 promoter. Inhibition of MLL1 blunted NF-κBp65 and NOX4 by modulating inflammatory and oxidative phenotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Such proof-of-concept study shows persistence of MLL1-dependent H3K4me3 in offspring born to GD women, suggesting an epigenetic-driven transmission of maternal phenotype. These findings may pave the way for pharmacological reprogramming of adverse histone modifications to mitigate abnormal phenotypes underlying early ASCVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471481/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471481</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae688>10.1093/eurheartj/ehae688</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471481</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nadia Di Pietrantonio</dc:creator>
<dc:creator>Julia Sánchez-Ceinos</dc:creator>
<dc:creator>Mariana Shumliakivska</dc:creator>
<dc:creator>Alexander Rakow</dc:creator>
<dc:creator>Domitilla Mandatori</dc:creator>
<dc:creator>Pamela Di Tomo</dc:creator>
<dc:creator>Gloria Formoso</dc:creator>
<dc:creator>Tiziana Bonfini</dc:creator>
<dc:creator>Maria Pompea Antonia Baldassarre</dc:creator>
<dc:creator>Maria Sennström</dc:creator>
<dc:creator>Wael Almahmeed</dc:creator>
<dc:creator>Assunta Pandolfi</dc:creator>
<dc:creator>Francesco Cosentino</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The inflammatory and oxidative phenotype of gestational diabetes is epigenetically transmitted to the offspring: role of methyltransferase MLL1-induced H3K4me3</dc:title>
<dc:identifier>pmid:39471481</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae688</dc:identifier>
</item>
<item>
<title>Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471463/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this multi-centre IPTW analysis, patients with severe ischaemic cardiomyopathy undergoing revascularization by CABG rather than PCI showed improved long-term survival. However, future randomized controlled trials are needed to confirm the effect of any such benefits.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae672. doi: 10.1093/eurheartj/ehae672. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The optimal revascularization strategy in patients with ischaemic cardiomyopathy remains unclear with no contemporary randomized trial data to guide clinical practice. This study aims to assess long-term survival in patients with severe ischaemic cardiomyopathy revascularized by either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Australian and New Zealand Society of Cardiac and Thoracic Surgeons and Melbourne Interventional Group registries (from January 2005 to 2018), patients with severe ischaemic cardiomyopathy [left ventricular ejection fraction (LVEF) &lt;35%] undergoing PCI or isolated CABG were included in the analysis. Those with ST-elevation myocardial infarction and cardiogenic shock were excluded. The primary outcome was long-term National Death Index-linked mortality up to 10 years following revascularization. Risk adjustment was performed to estimate the average treatment effect using propensity score analysis with inverse probability of treatment weighting (IPTW).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 2042 patients were included, of whom 1451 patients were treated by CABG and 591 by PCI. Inverse probability of treatment weighting-adjusted demographics, procedural indication, coronary artery disease extent, and LVEF were well balanced between the two patient groups. After risk adjustment, patients treated by CABG compared with those treated by PCI experienced reduced long-term mortality [adjusted hazard ratio 0.59, 95% confidence interval (CI) 0.45-0.79, P = .001] over a median follow-up period of 4.0 (inter-quartile range 2.2-6.8) years. There was no difference between the groups in terms of in-hospital mortality [adjusted odds ratio (aOR) 1.42, 95% CI 0.41-4.96, P = .58], but there was an increased risk of peri-procedural stroke (aOR 19.6, 95% CI 4.21-91.6, P &lt; .001) and increased length of hospital stay (exponentiated coefficient 3.58, 95% CI 3.00-4.28, P &lt; .001) in patients treated with CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this multi-centre IPTW analysis, patients with severe ischaemic cardiomyopathy undergoing revascularization by CABG rather than PCI showed improved long-term survival. However, future randomized controlled trials are needed to confirm the effect of any such benefits.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471463/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471463</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae672>10.1093/eurheartj/ehae672</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471463</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jason E Bloom</dc:creator>
<dc:creator>Sara Vogrin</dc:creator>
<dc:creator>Christopher M Reid</dc:creator>
<dc:creator>Andrew E Ajani</dc:creator>
<dc:creator>David J Clark</dc:creator>
<dc:creator>Melanie Freeman</dc:creator>
<dc:creator>Chin Hiew</dc:creator>
<dc:creator>Angela Brennan</dc:creator>
<dc:creator>Diem Dinh</dc:creator>
<dc:creator>Jenni Williams-Spence</dc:creator>
<dc:creator>Luke P Dawson</dc:creator>
<dc:creator>Samer Noaman</dc:creator>
<dc:creator>Derek P Chew</dc:creator>
<dc:creator>Ernesto Oqueli</dc:creator>
<dc:creator>Nicholas Cox</dc:creator>
<dc:creator>David McGiffin</dc:creator>
<dc:creator>Silvana Marasco</dc:creator>
<dc:creator>Peter Skillington</dc:creator>
<dc:creator>Alistair Royse</dc:creator>
<dc:creator>Dion Stub</dc:creator>
<dc:creator>David M Kaye</dc:creator>
<dc:creator>William Chan</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival</dc:title>
<dc:identifier>pmid:39471463</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae672</dc:identifier>
</item>
<item>
<title>Transcatheter correction of a rare combined anomalous pulmonary and systemic venous return in an adult</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39471415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241031082010&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 29:ehae732. doi: 10.1093/eurheartj/ehae732. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39471415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241031082010&v=2.18.0.post9+e462414">39471415</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae732>10.1093/eurheartj/ehae732</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39471415</guid>
<pubDate>Tue, 29 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Grégoire Albenque</dc:creator>
<dc:creator>Clément Batteux</dc:creator>
<dc:creator>Sébastien Hascoët</dc:creator>
<dc:date>2024-10-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter correction of a rare combined anomalous pulmonary and systemic venous return in an adult</dc:title>
<dc:identifier>pmid:39471415</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae732</dc:identifier>
</item>





























</channel>
</rss>